Abstracts Archive - Page 1474 of 2607 - ACR Meeting Abstracts

Abstract Number: 1301 • 2017 ACR/ARHP Annual Meeting
Congenital Heart Defects in Children Born to Mothers with Rheumatic Disease and Anti-Ro and/or Anti-La Antibodies
Julie Couture¹, Linda T Hiraki², Franklin Silverio¹, Deepika Sharma¹ and Earl Silverman³, ¹Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ²Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ³Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Transplacental passage of maternal anti-Ro IgG is thought to be critical in initiating inflammation leading to congenital heart block in neonatal lupus erythematosus (NLE).…
Abstract Number: 1302 • 2017 ACR/ARHP Annual Meeting
Luteinized Unruptured Follicle Syndrome in Young Female with Juvenile Idiopathic Arthritis
Renato B. B. Tomioka¹, Gabriela R.V. Ferreira², Nadia E Aikawa³, Gustavo A.R. Maciel¹, Paulo C. Serafini¹, Edmund Baracat¹, Lucia M A Campos⁴, Cláudia Goldenstein-Schainberg³, Rosa M R Pereira³, Eloisa Bonfa⁵ and Clovis A Silva², ¹Discipline of Gynecology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) may be active during reproductive age, therefore ovarian function and future fertility are relevant issues for its female population. Nonsteroidal…
Abstract Number: 1303 • 2017 ACR/ARHP Annual Meeting
Polycystic Ovarian Syndrome in Rheumatic Disease
Cuoghi Edens¹ and Maria Antonelli², ¹Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, ²Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Polycystic ovarian syndrome (PCOS) is a common entity in the general population associated with polycystic ovaries, oligomenorrhea, difficulty conceiving, hormone abnormalities, metabolic comorbidities, and…
Abstract Number: 1304 • 2017 ACR/ARHP Annual Meeting
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with SLE in Saginaw Valley, a High Risk Population
J. Patricia Dhar^1,2, Lynnette Essenmacher³, Renee Dhar⁴, Neli Ragina⁵ and Robert Sokol⁶, ¹Internal Medicine, Wayne State University School of Medicine, Detroit, MI, ²Internal Medicine, Central Michigan University College of Medicine, Saginaw, MI, ³Wayne State University School of Medicine, Detroit, MI, ⁴CMED medical student, Central Michigan University College of Medicine, Mt. Pleasant, MI, ⁵Foundational Sciences, Central Michigan University College of Medicine, Mount Pleasant, MI, ⁶Department of Obstetrics & Gynecology, Wayne State University School of Medicine, Detroit, MI
Background/Purpose: Women with SLE are at increased risk for cervical neoplasia likely due to infection with high risk (HR) HPV and thus should be considered…
Abstract Number: 1305 • 2017 ACR/ARHP Annual Meeting
Use of Estrogen-Containing Contraceptives Among SLE Women with and without Contraindications to Estrogen
Arielle Mendel¹, Sasha Bernatsky², Yvan St.Pierre³, Christian Pineau⁴ and Evelyne Vinet⁵, ¹Rheumatology, McGill University, Montreal, QC, Canada, ²Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁵Divisions of Rheymatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Estrogen-containing contraceptives may be contraindicated in specific medical conditions due to an increased risk of cardiovascular and thromboembolic events. Women with SLE are at…
Abstract Number: 1306 • 2017 ACR/ARHP Annual Meeting
Predictors of Contraceptive Use Among Reproductive-Age Women with Rheumatic Diseases
Mehret Birru Talabi¹ and Sonya Borrero², ¹Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Contraception helps reproductive-age women with rheumatic diseases to avoid or plan pregnancies so that disease quiescence on safe medications may first be achieved. However,…
Abstract Number: 1307 • 2017 ACR/ARHP Annual Meeting
Contraceptive Use in Patients with Rheumatologic Disease on Teratogenic Medications: Rate of Use and Related Factors
Shanley O'Brien¹ and Megan Krause², ¹Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology, and Rheumatology, Kansas University Medical Center, Kansas City, KS
Background/Purpose: Rheumatologic diseases can affect females of reproductive age. Medications utilized for treatment of these diseases can be associated with harmful consequences in pregnancy. Unfortunately,…
Abstract Number: 1308 • 2017 ACR/ARHP Annual Meeting
Answering Reproductive Health Questions That Your Patients Want to Know: Impediments to Family Building and Risks of Contraception
Malithi Jayasundara¹, Amanda M. Eudy², Tayseer Haroun³, W. Benjamin Nowell⁴, Jeffrey R. Curtis⁵, Rachelle Crow-Hercher⁶, Charlotte Whitney White⁶, Seth D. Ginsberg⁷ and Megan E. B. Clowse⁸, ¹Rheumatology, Duke University, Durham, NC, ²Duke University, Durham, NC, ³Department of Medicine/Division of Rheumatology, Duke University Medical Center, Durham, NC, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Arthritis Power, Upper Nyack, NY, ⁷Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁸Duke University Medical Center, Durham, NC
Background/Purpose: Women with arthritis wonder whether they will be able to have the children they desire. They also worry that oral contraceptives may worsen their…
Abstract Number: 1309 • 2017 ACR/ARHP Annual Meeting
Characteristics and Outcomes of Prospectively Reported Pregnancies Exposed to Certolizumab Pegol from a Safety Database
Megan E. B. Clowse¹, Angela E. Scheuerle², Christina D Chambers³, Anita Afzali⁴, Alexa Kimball⁵, John J. Cush⁶, Maureen Cooney⁷, Laura Shaughnessy⁷, Mark Vanderkelen⁸ and Frauke Förger⁹, ¹Division of Rheumatology, Department of Medicine, Duke University Medical Center, Durham, NC, ²UT Southwestern Medical Center, Dallas, TX, ³UC San Diego School of Medicine, San Diego, CA, ⁴University of Washington Harborview Medical Center, Seattle, WA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Baylor Scott & White Research Institute, Dallas, TX, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Braine-l’Alleud, Belgium, ⁹Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: Anti-tumor necrosis factor medications (anti-TNFs) are effective in controlling chronic inflammatory diseases, but information about their use and safety in pregnancy is limited. Consequently,…
Abstract Number: 1310 • 2017 ACR/ARHP Annual Meeting
Maternal and Fetal Outcomes in a Cohort of Patients Exposed to Tumor Necrosis Factor Inhibitors throughout Pregnancy
Geneviève Genest¹, Karen Spitzer² and Carl Laskin³, ¹Allergy-Immunology, McGill University and McGill University Health Center, Montreal, QC, Canada, ²Trio Fertility, Toronto, ON, Canada, ³Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) are increasingly used during pregnancy but are frequently withheld in the second or third trimester to minimize transplacental transfer…
Abstract Number: 1311 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcome in Chinese Women with Rheumatic Disease Treated By Leflunomide (LEF)
Yan Zhao¹, lingxun shen², zongwen shuai³, Hengli Zhao⁴, Weinan Lai⁵, Xiaoling Lai⁶, Shaoying Zhang⁷, Xuequn Wang⁸, Shaoxian Hu⁹, Wenli Chen¹⁰, Wei Ji¹¹, Hua Wei¹², Qi Zhang¹³, Lixia Pang¹⁴, huaxiang Liu¹⁵, Qiang Shu¹⁵, Jun-li Zhang¹⁶, Yating Zhou¹⁷, Qiong Jiang¹⁸, Huaxiang Wu¹⁹, Jing Xue¹⁹, Ganping Bai²⁰, Li Zhang²¹ and Fei Xiao²¹, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Wuhan Union Hospital, wuhan, China, ³The First Affiliated Hospital of Anhui University, Hefei, China, ⁴Yantai Hospital of Traditional medicine University, Yantai, China, ⁵Nanfang Hospital, Guangzhou, China, ⁶Guangxi Hospital of Traditional Chinese Medicine, Nanning, China, ⁷Yiling Hospital, Yiling, China, ⁸The First Affiliated Hospital of Xinyang, Xinyang, China, ⁹Tongji hospital, wuhan, China, ¹⁰Wuhan Central Hospital, wuhan, China, ¹¹Jiangsu Province Hospital of TCM, Nanjing, China, ¹²Subei People's Hospital, Yangzhou, China, ¹³Dongying central hospital, Dongying, China, ¹⁴Dongying Hospital, Dongying, China, ¹⁵Qilu hospital of Shandong University, Jinan, China, ¹⁶Rheumatology, The Fifth Hospital of Xi’an City, Xi’an, China, ¹⁷Xian No5 Hospital, Shandong, China, ¹⁸Taizhou Hospital, Taizhou, China, ¹⁹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, ²⁰Chongqing Southwest Hospital, Chongqing, China, ²¹Gothic Internet Technology Corporation, Shanghai, China
Background/Purpose: LEF is a first line DMARD. Due to the teratogenic effects in offspring of rats in preclinical study, the patients who plan to get…
Abstract Number: 1312 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Male Patients Using Anti-Tumor Necrosis Factor Alpha Patients with Inflammatory Arthritis; Hur-BIO Real Life Experiences
Oguz Abdullah Uyaroglu¹, Emrah Seyhoglu¹, Abdulsamet Erden², Levent Kilic², Berkan Armagan², Alper Sari², Omer Karadag³, Ali Akdogan², Sule Apras Bilgen³, Sedat Kiraz², Ihsan Ertenli³ and Umut Kalyoncu³, ¹Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: A significant part of patients with inflammatory arthritis are at their reproductive ages. Anti-tumor necrosis factor-alpha (Anti-TNF) agents are one of the relevant treatment…
Abstract Number: 1313 • 2017 ACR/ARHP Annual Meeting
Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Kristin Palmsten¹, Gretchen Bandoli², Diana L Johnson¹, Ronghui Xu^3,4 and Christina D Chambers¹, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Department of Mathematics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are limited data regarding gestational timing of oral corticosteroid (OCS) use during pregnancy and risk of preterm birth. The objective was to compare…
Abstract Number: 1314 • 2017 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Patients with Psoriasis: A Nationwide Population-Based Study
Meng-Jiun Chiou¹, Yu-Hui Huang², Chang-Fu Kuo¹, Kuang-Hui Yu¹, Shue-Fen Luo¹ and Yao-Fan Fang¹, ¹Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ²Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
Background/Purpose: The pregnancy outcomes in women with psoriasis have rarely been investigated. This nationwide population study aimed to estimate the risks of adverse maternal and…
Abstract Number: 1315 • 2017 ACR/ARHP Annual Meeting
Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Frauke Förger¹, Stephanie van den Brandt², Astrid Zbinden³, Monika Ostensen³ and Peter M. Villiger³, ¹Inselspital, University of Bern, Bern, Switzerland, ²Clinical Immunology and Rheumatology, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: To analyze pregnancy complications, pregnancy outcome and delivery mode in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).Methods: Patients with RA and axSpA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].